Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema

被引:2
作者
Varma, Rohit [1 ]
Bressler, Neil M. [2 ]
Doan, Quan, V [3 ]
Suner, Ivan J. [4 ]
Danese, Mark [3 ]
Dolan, Chantal M. [5 ]
Lee, Abraham [3 ]
Ehrlich, Jason S. [5 ]
Rajput, Yamina [5 ]
机构
[1] CHA Hollywood Presbyterian Med Ctr, Southern Calif Eye Inst, 1300 N Vermont Ave, Los Angeles, CA 90027 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Outcomes Insights Inc, Westlake Village, CA USA
[4] Retina Associates Florida, Tampa, FL USA
[5] Genentech Inc, San Francisco, CA 94080 USA
来源
CLINICAL OPHTHALMOLOGY | 2020年 / 14卷
关键词
diabetic macular edema; diabetic retinopathy; population-based model; PANRETINAL PHOTOCOAGULATION; INTRAVITREAL RANIBIZUMAB; RISK-FACTORS; TRIAMCINOLONE; PREVALENCE; THERAPY; BURDEN;
D O I
10.2147/OPTH.S236636
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Estimate effects of ranibizumab on diabetic retinopathy (DR) severity in US Hispanic and non-Hispanic white persons with center-involved diabetic macular edema (DME) causing vision impairment for whom ranibizumab treatment would be considered. Patients and Methods: This model simulated DR severity outcomes over 2 years in the better-seeing eye using US census, National Health and Nutrition Examination Survey, Wisconsin Epidemiologic Study of Diabetic Retinopathy, and Los Angeles Latino Eye Study data. Baseline DR severity estimated from Diabetic Retinopathy Clinical Research Network trial data. Changes in DR severity after 2 years, with/without monthly ranibizumab (0.3 or 0.5 mg), were estimated from Phase III clinical trial data (RIDE/RISE) using a 2-dimensional Monte Carlo simulation model. Number of patients over a 2-year period for whom 1) DR severity worsening was avoided, 2) DR severity improved, and 3) selected clinical events related to proliferative DR (PDR) occurred, was estimated. Results: An estimated 37,274 US Hispanic and non-Hispanic white persons were projected to have DR with center-involved DME and be eligible for ranibizumab treatment. The number of persons with moderately severe non-proliferative DR (NPDR) or less severe DR at baseline who would worsen to PDR and experience a PDR complication over 2 years would be reduced from 437 with no ranibizumab to 19 with ranibizumab (95% reduction; 95% simulation interval [SI], 79-100%). The number of persons with severe NPDR or less severe DR at baseline who would be expected to improve by >= 2 DR severity levels over 2 years would increase from 1706 with no ranibizumab to 13,042 with ranibizumab (682% increase; 95% SI, 478-967%). Conclusion: This model estimates that ranibizumab treatment in US Hispanic and non-Hispanic white patients with center-involved DME causing vision impairment would potentially reduce the number of patients with worsening DR and potentially increase the number with DR improvements.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 37 条
  • [1] [Anonymous], 1991, Ophthalmology, V98, P786
  • [2] [Anonymous], 2012, NAT HLTH NUTR EX SUR
  • [3] [Anonymous], 2014, National diabetes statistics report
  • [4] [Anonymous], 2010, 1 US CENS BUR
  • [5] [Anonymous], 2005, Prevention of Blindness from Diabetes Mellitus: Report of a WHO Consultation in Geneva, Switzerland
  • [6] [Anonymous], American Fact Finder
  • [7] Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy Long-Term Outcomes of the Phase III RIDE and RISE Trials
    Boyer, David S.
    Nguyen, Quan Dong
    Brown, David M.
    Basu, Karen
    Ehrlich, Jason S.
    [J]. OPHTHALMOLOGY, 2015, 122 (12) : 2504 - +
  • [8] CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB DRCR.net Protocol I 5-Year Report
    Bressler, Susan B.
    Odia, Isoken
    Glassman, Adam R.
    Danis, Ronald P.
    Grover, Sandeep
    Hampton, G. Robert
    Jampol, Lee M.
    Maguire, Maureen G.
    Melia, Michele
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 1896 - 1904
  • [9] Change in Diabetic Retinopathy Through 2 Years Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab
    Bressler, Susan B.
    Liu, Danni
    Glassman, Adam R.
    Blodi, Barbara A.
    Castellarin, Alessandro A.
    Jampol, Lee M.
    Kaufman, Paul L.
    Melia, Michele
    Singh, Harinderjit
    Wells, John A.
    [J]. JAMA OPHTHALMOLOGY, 2017, 135 (06) : 558 - 568
  • [10] Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial
    Bressler, Susan B.
    Qin, Haijing
    Melia, Michele
    Bressler, Neil M.
    Beck, Roy W.
    Chan, Clement K.
    Grover, Sandeep
    Miller, David G.
    [J]. JAMA OPHTHALMOLOGY, 2013, 131 (08) : 1033 - 1040